LEXEO Therapeutics
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single gene mutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
Domain
lexeotx.com
Country
United StatesIndustry
BiotechnologyEmployees
51-100
Last Funding
$154.0M
Founded
2017
Tech Stack (14 technologies)
Frequently Asked Questions
What technologies does LEXEO Therapeutics use?+
LEXEO Therapeutics uses 14 technologies including Google Analytics, Google Tag Manager, WordPress.
What industry is LEXEO Therapeutics in?+
LEXEO Therapeutics operates in the Biotechnology industry.
Where is LEXEO Therapeutics based?+
LEXEO Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026